Zacks Research Has Bearish Forecast for TSE:BHC Q2 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Research analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for Bausch Health Companies in a report issued on Wednesday, May 21st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.37 for the quarter, down from their previous estimate of $1.52. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.47 EPS, Q4 2025 earnings at $1.64 EPS, FY2025 earnings at $5.29 EPS, Q1 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $5.68 EPS, Q1 2027 earnings at $1.53 EPS and FY2027 earnings at $6.73 EPS.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at C$6.12 on Monday. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. The firm has a market capitalization of C$1.59 billion, a P/E ratio of -8.96, a P/E/G ratio of 0.21 and a beta of 0.77. The business has a fifty day simple moving average of C$7.45 and a two-hundred day simple moving average of C$9.66. Bausch Health Companies has a 12 month low of C$5.45 and a 12 month high of C$13.74.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.